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Abstract 
Purpose: To develop and determine the in vivo performance of a capsule-based pulsatile drug delivery 
system containing salbutamol sulphate  
Methods: A controlled pulsatile release of drug after a programmed 4 h lag period was achieved from 
cross-linked gelatin capsule shells containing salbutamol pellets, and sealed with a suitable mixture of 
sodium alginate and ethyl cellulose as plug.  In order to confirm the utility of developed system for the 
management of nocturnal asthma, a crossover study was conducted.   six  male rabbits were  fasted 
overnight and divided into two groups comprised of 3 rabbits each. The individual rabbits were 
administered the developed pulsatile capsule and immediate release salbutamol capsule as reference, 
separately. Blood samples were collected from the ear vein of the animals into heparinized tubes and 
used to determine pharmacokinetic parameters, namely, maximum plasma concentration (Cmax), time to 
reach maximum plasma concentration (Tmax), and area under the plasma concentration - time curve 
(AUC0-∞) using a validated HPLC method. 
Results: It was observed that drug release from the optimized time-controlled capsule stopped for a 
period of approximately 4.25 h with an average Cmax and Tmax of  271.54 ± 58.95 ng/ml and 6.00 ± 0.25 
h. The AUC0-∞ of salbutamol after administration of the time-controlled pulsatile system was 2494.73 ± 
525.95 ng h/ml while that of the immediate-release formulation was 2352.77 ± 432.51 ng h/ml.  Using 
ANOVA at a significant difference of p < 0.05 (CI 95%), there was no significant difference for the AUC0-
∞   between immediate release and the pulsatile capsule developed.  
Conclusion: The developed system is capable of releasing salbutamol after a 4 h lag period and can 
be considered as promising delivery system for time-controlled (pulsatile) delivery of  the medication for 
the management of nocturnal asthma. 
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Up till the early 1990s, efforts were mainly to 
design drug delivery systems which will release 
the drug at fairly constant rate. In fact, these 
systems turned to be one of the most successful   
systems in delivering the drug molecule [1]. But 
still for many of the drugs, use of such systems is 
not suitable because of a number of reasons. 
This is particularly true in cases where the drug 
is subjected to large metabolic degradation. Due 
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to ‘first pass effect’ there will be reduction in the 
bioavailability of the drug because gradual 
release can result in greater degradation. 
Secondly drugs with short half-life need to be 
administered repeatedly which results in patient 
non-compliance. Further, in the case of chronic 
treatment where the drug is given in sustained 
release dosage form, continuous exposure of the 
drug to body may lead to adverse effect. Lastly, 
drugs which exhibit tolerance should not be 
delivered at a constant rate, since the drug effect 
decreases with time at constant drug level. In 
such cases it is preferable to opt for a dosage 
form which will provide concentration of drug at 
particular time point only [2].  
 
Chronopharmaceutics, whereby research is 
devoted to the design and evaluation of drug 
delivery systems that release a therapeutic agent 
at a rhythm that ideally matches the biological 
requirement of a given disease therapy, has 
attracted some attention in recent times [3,4]. 
The objective of this study was to determine the 
in vivo behavior of a developed salbutamol 
pulsatile capsule for the management of 
nocturnal asthma. Capsule is designed to have a 
release off period of 4 hour [5,6]. The developed 
system has already shown positive results during 
in vitro studies [7]. Ideally, an animal model that 
suitably mimics human physiological system 
should be chosen for in vivo studies. In this 
regard, animals such as monkeys, pigs and dogs 
have been suggested [9]. However, since these 
animals are difficult to handle, rabbit was chosen 







Salbutamol sulphate (Ranbaxy Research 
Laboratories, Gurgaon, India), microcrystalline 
cellulose (Avicel PH101, Jubiliant Organosys, 
New Delhi India), Eudragit L 100 and S 100 
(Rohm Pharma, GmbH Germany) Sodium 
alginate, HPMC, Polyethylene oxide, 
Ethylcellulose (Ranbaxy Research Laboratories, 
Gurgaon, India) were obtained as gifts from the 
indicated sources. Acetonitrile HPLC grade and 
methanol HPLC grade were purchased from JT 
Baker (USA). Salbutamol and standards were 
purchased from Sigma Aldrich (USA). All other 
chemicals used were of analytical grade 
 
Development of pulsatile drug delivery 
system  
 
The pulsatile capsule was aimed to provide a 
total lag time of approximately 4 h. The basic 
design of the proposed dosage form consisted of 
an insoluble capsule body filled with drug loaded 
pellets sealed with hydrocolloid plug, and a 
soluble capsule cap. Hydrocolloid plug was 
inserted to stop the release of pellets for a period 
of 2 h. The plugged capsule was further coated 
with enteric polymer (Eudragit S100: Eudragit 
L100, 4:1) to provide a additional 2 hour lag time 
and to minimize the gastric transit time variability. 
Finally, a total of 4-h lag time was achieved using 
hydrocolloid plug material together with outer 
enteric coating of sealed capsule.  Enteric 
coating was expected to be dissolved at pH 6.8. 
Pellets were prepared by extrusion and 
spheronization using 2 % w/v of PVP K30 as 
binder and water as granulating liquid. In order to 
prepare insoluble gelatin capsule bodies, the 
empty gelatin capsule bodies were exposed to 
formalin vapors generated by a reaction between 
15 %v/v formaldehyde solution and potassium 
permanganate. The caps of the capsules were 
not subjected to the above treatment, leaving 
them water soluble.  
 
Rapidly disintegrating pellets were prepared by 
extrusion, spheronization method. Drug and 
excipients were preblended and sieved through 
0.420 mm mesh screen. Ac DiSol (3 %w/w) as 
disintegrant and 2 % PVP K-30 aqueous 
solution, as binding agent, were added to mixed 
powders to achieve proper consistency and 
kneaded properly. The pellets were evaluated for 
flow properties, surface morphology and in vitro 
dissolution behavior. Optimized pellets were filled 
in to insoluble capsule, plugged with hydrocolloid 
material to provide the desired delay in release 
and coated with enteric polymer which was 
required to be dissolved in pH 6.8 to avoid 
gastric emptying variations [9]. 
 
The dissolution behavior of the developed 
system was studied in pH 1.2 and phosphate 
buffer pH 6.8 media. For the initial 2 h, the 
system was exposed to 0.1M HCl after that 
media was changed to pH 6.8 phosphate buffer 
to simulate lower intestinal pH.  
 
After in-vitro optimization, in-vivo studies were 
carried out in healthy rabbits to validate the 
developed system. The calibration curves were 
constructed by spiking drug-free plasma with 
known amount of salbutamol at concentrations of 
5.0 - 400.0 ng/ml. The standard calibration curve 
(n = 6) was found to be linear over the 
concentration range used with a correlation 
coefficient of 0.9999. The samples were 
quantified using peak height ratio of salbutamol 
over the internal standard.  
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The pharmacokinetic study was performed in 
accordance with the guidelines of the National 
Institutes of Health (10) and was approved by the 
Ethical Committee for Animal Experimentation of 
Hamdard University, India. The study was 
conducted using 6 male rabbits (3.0 - 3.5 kg). 
The rabbits were fasted overnight for at least 12 
h prior to the study. The 6 rabbits were divided 
into two groups with three rabbits in each group. 
In the first phase of the study, the rabbits in 
group 1 received optimized formulation and 
those in group 2 received immediate release 
capsule as reference. After a washout period of 7 
days, the rabbits were crossed-over and 
administered the alternate formulation. Both 
optimized formulation and reference containing 
equivalent of 5 mg of salbutamol sulphate were 
administered orally. The animals were fed 4 h 
after drug dosing and had free access to water 
throughout the study period. Blood samples of 2 
ml were collected though the marginal ear vein 
into heparinized tubes at regular time intervals. 
Blood samples were centrifuged at 4,000 rpm 
(Labofuge 200, Germany) for 5 min. The 
supernatant was transferred to empty glass 
tubes and stored at -70 °C until further analysis.  
Pharmacokinetic parameters, namely, maximum 
plasma concentration (Cmax), time to reach 
maximum plasma concentration (Tmax), and area 
under the plasma concentration- time curve 
(AUC0-∞), were obtained from plasma 
concentration versus time profiles. Cmax and Tmax 
were derived directly from the in vivo data. The 
area under the plasma salbutamol concentration 
time curve (AUC0-t) was calculated by the 
trapezoidal rule. AUC0-∞ was the summation of 
area under plasma salbutamol concentration-
time curve from zero to time t (AUC0-t) and area 
under plasma salbutamol concentration-time 
curve from time t to infinity (AUC t-∞). AUC t-∞ was 
calculated by dividing the last measurable 
plasma concentration with the terminal 
elimination rate constant (Ke). The value of Ke 
was the slope of logarithmic transformation of the 
terminal plasma concentration-time curve 
 
Plasma treatment and determination of 
salbutamol concentration 
 
The method reported by Xiao-Li et al with a slight 
modification was used for the determination. 
Supelco LC-18 solid phase extraction (SPE) 
columns (1 ml) were used for this purpose. The 
column was washed with methanol and water 1 
ml each. The internal standard solution, 
bamethan (0.2 μg/ml) and 1 ml of the plasma 
sample were passed into the column. After 2 
min, mild suction was applied to allow the sample 
to pass through the column. The suction was 
increased to expel all the trapped liquid from the 
column. The column was washed with water 
three times followed by acetonitrile once. Then 2 
ml methanol was passed through the column to 
elute the internal standard and the drug from the 
sorbent. The eluted liquid was dried at 40 °C 
under a gentle stream of nitrogen gas. The 
residue obtained was reconstituted with 50 μl of 
mobile phase and 40 μl was injected into the 
system [10].  
 
The HPLC system comprised of Waters pump 
(Model 510, Milford, MA, USA) equipped with 
sample injection port (7725i Rheodyne, Cotati, 
California, USA) fitted with 50 μl sample loop, a 
RF- 10Axl fluorescence detector (Shimadzu, 
Tokyo, Japan) and Chromato-integrator (D-2500, 
Hitachi, Tokyo, Japan). The analytical column, 
Luna C18 (2) (5 μm, 250 x 4.6 mm ID) column 
(Phenomenex, USA) fitted with a refillable guard 
column (Upchurch Scientific, Oak Harbour, WA, 
USA) packed with Perisorb RP-18 (30 - 40 μm, 
pellicular) was used for elution of salbutamol. 
The analysis was run at a flow-rate of 0.8 ml/min. 
The mobile phase consisted of phosphate buffer 
(pH 2.5), methanol and acetonitrile (890:170:20, 
v: v: v), the excitation and emission wavelengths 




Drug plasma concentration and pharmacokinetic 
parameters were analyzed by Wilcoxon Signed 
Rank test for paired samples and analysis of 
variance (ANOVA) at 95 % confidence limit. 
Difference between two related means was 




Characteristics of pellets 
 
Rapidly disintegrating pellets with good flow 
properties, smooth surface, a narrow particle size 
distribution and optimum elasticity and plasticity 
of the mass were obtained by combining Avicel 
PH 101 and lactose in the ratio of 70:20, together 
with 5 % drug, 3 % AcDiSol, and 2 % PVP K30. 
The yield, flow rate and mean particle size of the 
optimized pellet formulation were 74.65 %, 21.63 
g/sec and 889.6 µm, respectively.  
 
Formulation of hydrocolloid plug 
 
A total of 4 h lag time was intended for this 
pulsatile capsule. The plug was designed to 
provide 2 h lag time and the remaining 2 h was 
aimed to achieved by enteric coating. The 
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formulation sealed with 10, 20 and 30 mg of 
sodium alginate as plug material showed lag time 
of 0.15 ± 0.010 h, 1 ± 0.15 and 1.5 ± 0.25 h, 
respectively. At the end of 2 h, 87.98 and 42.11 
% drug release was observed from formulations 
plugged with 20 and 30 mg of sodium alginate, 
respectively. On the basis of plug ejection time 
and release profile obtained, sodium alginate 20 
mg was selected for further study.  
 
Ethyl cellulose (5, 10 and 15 mg) as a release 
modifier was added to replace the sodium 
alginate in the mixture to overcome the problem 
of drug leaching before the actual ejection of the 
plug. A plug made up of sodium alginate and 
ethyl cellulose (1:1, 20 mg) was considered as 
optimized plug since it was able to stop drug 
release frompellets for the required period of 2 h 
(Fig 1). 
 
Enteric-coated plugged capsule 
 
In order to achieve the complete lag time of 4 h 
as indicated above, the capsule plugged with 
hydrocolloid material was further coated with 
enteric polymer. On the basis of results obtained 
after disintegration and dissolution analysis of 
various enteric polymers and their combinations 
in 0.1 M HCl and pH 6.8 phosphate buffer, 
capsules coated with 6 %w/w coat of a mixture of 
Eudragit S100 and L100 (4:1) was considered to 
be optimized in terms of providing a lag time to 2 
h and a total lag time of 4 h (Table 1). 
 
Animal study for developed pulsatile capsule. 
The limit of quantification (LOQ) was set at 5.0 
ng/ml, which was the lowest concentration used 
in constructing the standard calibration curve. 
The limit of detection was 1 ng /ml. Inter-day 
accuracy ranged between 91.28 and 102.45 % 
with precision between 1.90 and 9.26 %. Intra-
day accuracy ranged between 89.92 and 108.11 
% with precision between 0.65 and 10.24 %. 
 
Drug release from the optimized time-controlled 
capsule was halted for a period of approximately 
4 ± 0.25 h with mean Cmax and Tmax of 271.54 ± 
58.95 ng /ml and 6.0 ± 0.25 h, respectively. Drug 
absorption from IR capsule was rapid without lag 
time. Mean Cmax and Tmax values obtained after 
administration of IR capsule were 260.35 ± 54.19 
ng/ml and 2.0 ±0.25 h, respectively. The AUC0-∞ 
of salbutamol after administration of time-
controlled pulsatile system was 2494.73 ± 525.95 
ng h/ml while that of the immediate release 
formulation was 2352.77 ± 432.51 ng h/ml.  
There was a statistically significant difference 
(p≤0.05) between the Tmax values of the two 
formulations. However, there was no significant 
difference (p≤0.05) in Cmax and AUC0-∞ values 
between the two formulations (Fig 3). 
 
 
Fig 1: In vitro release profile of pulsatile capsule 
plugged with various amounts of ethyl cellulose (EC) 
and sodium alginate (SA) mixture; = 15mg SA and 5 
mg EC,   = 10 mg SA and 10 mg EC,  = 5 mg SA 
and 15 mg EC 
 
Almost 97.65 % drug was released in pH 6.8 in a 
period of 2.25 h (Fig 2). 
 
 
Fig 2: Dissolution profile of optimized dosage form in 
0.1M HCl (initial 2 h) and then in pH 6.8 phosphate 
buffer.
 
Table 1: Effect of disintegration and dissolution on formulations of various combinations of Eudragit S100 and L 
100 with various levels of enteric coating 
 
Parameter S100 L 100 S100:L100 (1:1 ) S100:L100 (2:1 ) S100:L100    (4:1) 
Coating level (% w/w) 4 6 8 4 6 8 4 6 8 4 6 8 4 6 8 
Disintegration test   F P P F   F P P F P P P P P 
Solubility in pH 5.5 -- S NS -- S S - S S - S S S NS NS 
Avg. lag time in pH 6.8  (h) -- 1.3 2.8 -- 1.3 1.3 -- 1.3 1.8 - 1.3  1.9 2.0 2.3 
F = Failed, P = Passed, S = Soluble, NS = Not soluble.  
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Fig 3: Comparative plasma drug concentration vs. 
time profiles of immediate release (  ) and pulsatile 




The developed system is based on the 
combination of pH sensitive (enteric) coating and 
time-controlled (plug) delivery.  
Schiff’s base condensation phenomenon has 
been employed to modify the solubility of gelatin 
capsule bodies. On exposure to formalin vapors, 
amino group present in the gelatin (capsule shell) 
molecular chain undergoes cross linking with 
aldehyde group present in formaldehyde 
molecule as per Schiff’s base condensation 
resulting in decreased aqueous solubility of 
gelatin [11]. The present study revealed that 
Avicel PH 101 in combination with lactose 
formed pellets with smooth surface 
characteristics. With increase in lactose 
concentration, a decrease in the yield, increase 
in friability and generation of fines were 
observed. At increased Avicel PH 101 content, 
mean particle diameter decreased and most 
pellets formed were spherical with even particle 
size distribution. Since sodium alginate has lower 
mechanical strength and is sticky, the plug was 
completely detached from the capsule, leading to 
complete and immediate release after the 
desired lag period [12].  
 
A 6 % w/w coat of Eudragit S100 and L100 in 
ratio of 4:1 was found to be optimum since the 
coat was intact after 2 h disintegration analysis in 
0.1M HCl which indicates the ability of the coat to 
withstand gastric acid conditions. During 
dissolution studies it was observed that the coat 
was completely dissolved in pH 6.8 which 
confirms the release of the drug in the duodenum 
part  specified region of small intestine to 
maintain the desired lag time of 2 h. The soluble 
cap of the capsule had dissolved completely after 
15-20 min and thus exposed the polymer plug 
which absorbed the surrounding fluid, swelled 
and released the drug through the swollen 
matrix. Following complete wetting of the plug, it  
formed a soft mass which was then easily 
ejected out of the capsule body by erosion 
mechanism, thus releasing the pellets into the 
medium which readily dissolved and complete 
drug release was achieved after a lag time of 
4.25 h. 
 
There was statistically significant difference 
between the Tmax values of the two formulations. 
However, there was no statistical significant 
difference between the two formulations with 
regard to Cmax and AUC0-∞ values. The in-vitro 
results are supported by the in vivo data in terms 




The in vivo study supports the capability of the 
developed pulsatile release system to delay drug 
release in the gastrointestinal tract after 4-h lag 
time. Thus, the developed capsule-based 
delivery system can be considered a promising 
formulation for time-controlled delivery of 
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